Insulin Lispro
- Generic Name
- Insulin Lispro
- Brand Names
- Admelog, Humalog, Humalog Mix, Humalog kwikpen, Liprolog, Lyumjev, Insulin lispro Sanofi, Lyumjev (previously Liumjev)
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 133107-64-9
- Unique Ingredient Identifier
- GFX7QIS1II
- Background
Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin is release...
- Indication
本品尤其适用于下列情况：
1.经常发生低血糖的1型糖尿病者，使用本品可减少低血糖的发生率；
2.生活不规律，外出活动较多的用胰岛素治疗的糖尿病患者，本品快速、短效的特点有助于及时调整胰岛素的用量。
- Associated Conditions
- Diabetes Mellitus, Diabetic Ketoacidosis, Gestational Diabetes Mellitus (GDM)
- Associated Therapies
- -
Study of HDV Insulin Versus Insulin in Type 1 Diabetes Subjects (ISLE-1)
- Conditions
- Interventions
- First Posted Date
- 2016-06-08
- Last Posted Date
- 2018-07-31
- Lead Sponsor
- Diasome Pharmaceuticals
- Target Recruit Count
- 157
- Registration Number
- NCT02794155
- Locations
- 🇺🇸
Desert Endocrinology Clinical Research Center, Henderson, Nevada, United States
🇺🇸Rocky Mountain Diabetes & Osteoporosis Center, PA, Idaho Falls, Idaho, United States
🇺🇸California Medical Research Associates Inc., Northridge, California, United States
A Study of Treprostinil and a New Formulation of LY900014 in Healthy Japanese Participants
- Conditions
- Interventions
- First Posted Date
- 2016-05-12
- Last Posted Date
- 2020-06-04
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 23
- Registration Number
- NCT02770521
- Locations
- 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fukuoka, Japan
A Study of LY900014 in Participants With Type 2 Diabetes on Insulin Injection Therapy
- First Posted Date
- 2016-03-09
- Last Posted Date
- 2020-06-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 30
- Registration Number
- NCT02703337
- Locations
- 🇩🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Neuss, Germany
A Study of LY900014 Formulation in Participants With Type 1 Diabetes Mellitus Using Insulin Pumps
- First Posted Date
- 2016-03-09
- Last Posted Date
- 2020-06-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 30
- Registration Number
- NCT02703324
- Locations
- 🇩🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Neuss, Germany
A Study of LY900014 in Participants With Type 1 Diabetes on Insulin Injection Therapy
- First Posted Date
- 2016-03-09
- Last Posted Date
- 2020-06-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 30
- Registration Number
- NCT02703350
- Locations
- 🇩🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Mainz, Germany
Insulin Requirement for Pure-protein Meal in Children With Type 1 Diabetes on Insulin Pumps.
- Conditions
- Interventions
- First Posted Date
- 2016-02-18
- Last Posted Date
- 2016-07-29
- Lead Sponsor
- Medical University of Warsaw
- Target Recruit Count
- 70
- Registration Number
- NCT02685449
- Locations
- 🇵🇱
Medical University, Warsaw, Poland
A Study of a Novel Insulin Lispro Formulation in Participants With Type 1 Diabetes Mellitus Using Insulin Pumps
- First Posted Date
- 2015-12-07
- Last Posted Date
- 2017-07-13
- Lead Sponsor
- Eli Lilly and Company
- Registration Number
- NCT02623478
A Study of a New Type of Insulin in Participants With Type 1 Diabetes on Insulin Injection Therapy
- First Posted Date
- 2015-12-07
- Last Posted Date
- 2017-07-13
- Lead Sponsor
- Eli Lilly and Company
- Registration Number
- NCT02623452
A Study of a New Type of Insulin in Participants With Type 2 Diabetes on Insulin Injection Therapy
- First Posted Date
- 2015-12-07
- Last Posted Date
- 2017-07-13
- Lead Sponsor
- Eli Lilly and Company
- Registration Number
- NCT02623465
Assessment of the Safety of SAR342434 and Humalog® When Administered as Continuous Subcutaneous Insulin Infusion
- First Posted Date
- 2015-11-11
- Last Posted Date
- 2016-05-19
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 27
- Registration Number
- NCT02603510
- Locations
- 🇺🇸
Investigational Site Number 840002, Little Rock, Arkansas, United States
🇺🇸Investigational Site Number 840001, Denver, Colorado, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.